Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

Éric Bruckert, Robert A. Hegele, Jan Albert Kuivenhoven et al. · European Heart Journal · 2014 · 1.1K citations · Full text

Medicine, Cardiology, Genetics +17

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Frederick E. Dewey, Viktoria Gusarova, Richard L. Dunbar et al. · New England Journal of Medicine · 2017 · 875 citations · Full text

Medicine, Genetics, Molecular Genetics +15

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Terry A. Jacobson, Matthew K. Ito, Kevin C. Maki et al. · Journal of clinical lipidology · 2015 · 785 citations

Medicine, Endocrinology, Internal Medicine +15

Evinacumab for Homozygous Familial Hypercholesterolemia

Frederick J. Raal, Robert S. Rosenson, Laurens F. Reeskamp et al. · New England Journal of Medicine · 2020 · 764 citations · Full text

Medicine, Genetics, Molecular Genetics +17

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Marina Cuchel, Emma A. Meagher, Hendrik du Toit Theron et al. · The Lancet · 2012 · 740 citations · Full text

Life Sciences, Pharmacokinetics, Pharmacology +12